Wire · opportunities
Insight Molecular Diagnostics posts Q2 results, FDA AIR
◆ Sectors
Diagnostics
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Insight Molecular Diagnostics reported Q2 2026 financial results and disclosed receiving an FDA Additional Information Request (AIR) concerning its GraftAssureDx test; the company has 180 days to respond and anticipates a follow-up FDA meeting before Q4 2026.
This Wire brief sits within Fusion42's coverage of Diagnostics.
◆ ◆ The Wire takeaway
FDA's AIR sets a fixed deadline that forces you to prioritise regulatory compliance aggressively in the next six months. You must map out resources now to meet the 180-day FDA deadline or risk delaying market access for your diagnostic product.
◆ Coverage
1 source · 10 Aug 2026
◆ Related on Wire
◆ Topics
Diagnosticsfdaairdiagnosticsregulatory-processq2-results